Forty years of changes and thinking on China’s drug regulation

SONG Ruilin; LI Xinyi; ZHANG Fan; ZHANG Yangyang; PEI Xiaoyu

doi:10.6039/j.issn.1001-0408.2024.24.01

您当前的位置：

首页 >

文章列表页 >

Forty years of changes and thinking on China’s drug regulation

更新时间：2025-09-24

- Forty years of changes and thinking on China’s drug regulation
- ZHONGGUO YAOFANG Vol. 35, Issue 24, Pages: 2965-2971(2024)
- 作者机构：
  
  1.中国医药创新促进会，北京　100007
  2.中国药科大学国家药物政策与产业经济研究中心，南京　211198
  3.中国药科大学监管科学研究院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.24.01
  CLC： R95
- Received：09 October 2024，
  
  Revised：2024-11-28，
  
  Accepted：06 December 2024，
  
  Published：30 December 2024
- 稿件说明：
移动端阅览
宋瑞霖,李心怡,张帆,等.中国药品监管40年变迁与思考[J].中国药房,2024,35(24):2965-2971.

SONG Ruilin,LI Xinyi,ZHANG Fan,et al.Forty years of changes and thinking on China’s drug regulation[J].ZHONGGUO YAOFANG,2024,35(24):2965-2971.
宋瑞霖,李心怡,张帆,等.中国药品监管40年变迁与思考[J].中国药房,2024,35(24):2965-2971. DOI： 10.6039/j.issn.1001-0408.2024.24.01.

SONG Ruilin,LI Xinyi,ZHANG Fan,et al.Forty years of changes and thinking on China’s drug regulation[J].ZHONGGUO YAOFANG,2024,35(24):2965-2971. DOI： 10.6039/j.issn.1001-0408.2024.24.01.

摘要

自1984年第一部《药品管理法》颁布至今，我国药品监管已经走过40年历程。40年来，我国药品监管体系逐步从粗放走向精细，监管理念也日趋科学化。本文阐述了新中国成立以来我国药品监管法规制度改革的历史沿革，重点还原了从1984年到2001年期间《药品管理法》修订的历史渊源；梳理了随着产业创新发展不断出现的药品监管新挑战以及我国药品审评审批制度随之做出的相应改革措施，归纳了药品监管的改革成效；通过研究分析产业国际化背景下我国药品监管在监管能力、监管资源以及监管体系等方面仍面临的挑战，提出了建立跨区域监管体制、改革审评机制、加强审评队伍建设以及提升监管透明度等以促进医药产业高质量发展的政策建议。

Abstract

ince the first

Drug Administration Law

was issued in 1984， the drug

regulation of China has undergone a forty-year process. During these four decades， China’s drug regulatory system has gradually transitioned from being extensive to refined， and the concept of supervision has become increasingly scientific. This paper first outlines the historical evolution of China’s drug regulatory laws and regulations since the founding of the People’s Republic of China， with a focus on the historical origins of the revision of the

Drug Administration Law

during 1984-2001. It also clarifies the new challenges faced by drug regulation as the industry innovates and develops， as well as the corresponding reform of the drug review and approval system. The paper summarizes the reform achievements of drug regulation. By studying and analyzing the challenges faced by drug regulation in terms of regulatory capacity， regulatory resources， and regulatory system in the context of internationalization of the industry， the paper proposes policy suggestions such as establishing a cross-regional regulatory system， reforming the review mechanism， strengthening the construction of the review team， and enhancing transparency in regulatory practices， with the aim of promoting the high-quality development of the pharmaceutical industry.

关键词

Keywords

references

胡颖廉 . 中国药品监管体制改革25年回顾 [J ] . 中国食品药品监管， 2023 （ 3 ）： 4 - 15 ， 124 - 125 .

HU Y L . Retrospection of drug regulatory system reform in China through 1998-2023 [J ] . China Food Drug Adm Mag ， 2023 （ 3 ）： 4 - 15 ， 124 - 125 .

中国医药报 . 药品监管法治建设与时俱进 [EB/OL ] .（ 2018-12-13 ）[ 2024-11-24 ] . http：//health.china.com.cn/2018-12/13/content_40611870.htm http://health.china.com.cn/2018-12/13/content_40611870.htm .

China Medicine . Advancing with the times in the rule of law construction of drug supervision [EB/OL ] .（ 2018-12-13 ）[ 2024-11-24 ] . http：//health.china.com.cn/2018-12/13/content_40611870.htm http://health.china.com.cn/2018-12/13/content_40611870.htm .

李怡秋 . 晋江特大假药案始末 [J ] . 检察风云， 2018 （ 19 ）： 64 - 66 .

LI Y Q . The whole story of Jinjiang extraordinarily se-rious counterfeit drug case [J ] . Prosec View ， 2018 （ 19 ）： 64 - 66 .

陈新，黄清竹，温宝书 . 药品审评中心解决化学仿制药注册申请积压工作汇总及分析 [J ] . 中国新药杂志， 2017 ， 26 （ 18 ）： 2136 - 2142 .

CHEN X ， HUANG Q Z ， WEN B S . Introduction and analysis of CDE’s effort in solving backlog of generic drug registration applications [J ] . Chin J New Drugs ， 2017 ， 26 （ 18 ）： 2136 - 2142 .

佟梁慧，张帆，孙潭霖，等 . 中国临床试验数据监管改革的分析与思考 [J ] . 世界临床药物， 2023 ， 44 （ 8 ）： 882 - 890 .

TONG L H ， ZHANG F ， SUN T L ， et al . Analysis and thinking on the reform of clinical trial data supervision in China [J ] . World Clin Drug ， 2023 ， 44 （ 8 ）： 882 - 890 .

澎湃新闻 . 国家食药监总局加入ICH：中国制药行业将实施国际最高标准 [EB/OL ] .（ 2017-06-20 ）[ 2024-11-04 ] . https：//www.thepaper.cn/newsDetail_forward_1712895 https://www.thepaper.cn/newsDetail_forward_1712895 .

The Paper . National Medical Products Administration joins ICH：China’s pharmaceutical industry will implement the highest international standards [EB/OL ] .（ 2017-06-20 ）[ 2024-11-04 ] . https：//www.thepaper.cn/newsDetail_forward_1712895 https://www.thepaper.cn/newsDetail_forward_1712895 .

IQVIA Institute for Human Data Science . Global trends in R&D 2024：activity，productivity，and enablers [EB/OL ] .（ 2024-02-22 ）[ 2024-11-27 ] . https：//www.iqvia.com/in-sights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2024-activity-productivity-and-enablers https://www.iqvia.com/in-sights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2024-activity-productivity-and-enablers .

国家药品监督管理局 . 对十四届全国人大一次会议第1676号建议的答复 [EB/OL ] .（ 2023-06-28 ）[ 2024-11-27 ] . https：//www.nmpa.gov.cn/zwgk/jyta/rdjy/2023062811104-5131.html https://www.nmpa.gov.cn/zwgk/jyta/rdjy/2023062811104-5131.html .

National Medical Products Administration . Reply to re-commendation No. 1676 of the First Session of the 14th National People’s Congress [EB/OL ] .（ 2023-06-28 ）[ 2024-11-27 ] . https：//www.nmpa.gov.cn/zwgk/jyta/rdjy/202306-28111045131.html https://www.nmpa.gov.cn/zwgk/jyta/rdjy/202306-28111045131.html .

Food and Drug Administration . FDA dashboards：inspections [EB/OL ] . [ 2024-10-27 ] . https：//datadashboard.fda.gov/ora/cd/inspections.htm https://datadashboard.fda.gov/ora/cd/inspections.htm .

厉程，葛渊源，陈桂良 . 加入PIC/S与推进我国药品监管国际化的思考 [J ] . 中国药事， 2023 ， 37 （ 5 ）： 491 - 498 .

LI C ， GE Y Y ， CHEN G L . Joining PIC/S and thinking on promoting the internationalization of China’s drug regulation [J ] . Chin Pharm Aff ， 2023 ， 37 （ 5 ）： 491 - 498 .

张帆，张志娟，宋瑞霖 . WHO监管评估体系概况及对我国药品监管国际化的思考 [J ] . 中国食品药品监管， 2024 （ 7 ）： 16 - 25 .

ZHANG F ， ZHANG Z J ， SONG R L . Overview of WHO regulatory assessment system and reflection on the internationalization of China’s drug regulation [J ] . China Food Drug Adm Mag ， 2024 （ 7 ）： 16 - 25 .

上海市药监局 . 上海市药品监督管理局年报：2023年度 [EB/OL ] .（ 2024-04-17 ）[ 2024-10-27 ] . https：//yjj.sh.gov.cn/shsypjdgljnb2023/index.html https://yjj.sh.gov.cn/shsypjdgljnb2023/index.html .

Shanghai Drug Administration . Annual report of Shanghai Drug Administration：2023 [EB/OL ] .（ 2024-04-17 ）[ 2024-10-27 ] . https：//yjj.sh.gov.cn/shsypjdgljnb2023/index.html https://yjj.sh.gov.cn/shsypjdgljnb2023/index.html .

医药经济报 . 云南：加强专业化药品检查队伍建设 [EB/OL ] .（ 2022-08-15 ）[ 2024-10-27 ] . http：//www.yyjjb.com.cn/yyjjb/202208/20220815110641641_13084.shtml http://www.yyjjb.com.cn/yyjjb/202208/20220815110641641_13084.shtml .

Medicine Economic News . Yunnan：strengthen the construction of specialized drug inspection teams [EB/OL ] .（ 2022-08-15 ）[ 2024-10-27 ] . http：//www.yyjjb.com.cn/yy-jjb/202208/20220815110641641_13084.shtml http://www.yyjjb.com.cn/yy-jjb/202208/20220815110641641_13084.shtml .

袁利佳，杨志敏 . 国外药品审评专家咨询制度在药品审评体系中的作用及思考 [J ] . 中国药事， 2021 ， 35 （ 5 ）： 558 - 564 .

YUAN L J ， YANG Z M . The role and consideration of expert consultation in drug evaluation system [J ] . Chin Pharm Aff ， 2021 ， 35 （ 5 ）： 558 - 564 .

Views

299

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰